Complications of coronary interventions include adverse events associated with vascular access, manipulation of the coronary arteries, lesion dilatation, device implantation and the pharmacological treatments accompanying the procedure. They may involve an epicardial vessel, the microcirculation, the myocardium or other organs, and may occur during the intervention, in the following hours or later. Percutaneous coronary intervention, or PCI, modifies pre-existing disease through mechanical and biological intervention: its outcome depends both on immediate procedural success and on the vessel-wall response and prevention of subsequent events.
An event after PCI is not automatically a complication caused by the procedure. A patient may experience progression of coronary artery disease in another segment, heart failure resulting from the initial infarction, unrelated arrhythmias or noncardiac pain. Likewise, an initially satisfactory angiographic result does not exclude late problems in the treated segment. Assessment must establish the temporal and anatomical relationship with the intervention, identify the mechanism and estimate the amount of myocardium or organ function at risk. This approach allows emergencies to be identified without attributing every symptom to the stent.
It is not scientifically appropriate to assign a single risk to every procedure. Elective PCI of a simple lesion, treatment during myocardial infarction with shock, and complex recanalization of a chronic occlusion involve different populations, objectives and hazards. Reported percentages also depend on the definitions used for bleeding, kidney injury or procedure-related infarction, and on the intensity of surveillance. Risk assessment must be proportionate to the expected benefit of revascularization and include medical or surgical alternatives when appropriate.
Patient-related factors affect both the likelihood of a complication and the capacity to tolerate it. Biological age, frailty, anemia, renal impairment, diabetes, previous bleeding and the need for anticoagulation may influence the strategy. Reduced ventricular function leaves less reserve during a transient interruption of flow; shock alters renal perfusion, coagulation and drug absorption. Bleeding and ischemic risks often coexist, especially in patients with kidney disease or diffuse disease: they are not mutually exclusive categories that can be managed with one standard choice.
Coronary anatomy influences technical difficulty and outcome. Extensive calcification, tortuosity, bifurcations, ostial lesions, small vessels, long segments and chronic occlusions may complicate device delivery and uniform stent expansion. A high thrombus burden increases the possibility of distal embolization; degenerated saphenous vein grafts have particular features of fragility and embolization. Involvement of the left main coronary artery or the last functioning vessel magnifies the consequences of impaired flow. Complexity should guide preparation, equipment, imaging and the availability of bailout strategies.
Procedural factors include vascular access, catheter size and support, guidewire manipulation, the ratio between device and vessel diameter, dilatation pressures and plaque preparation. A calcified lesion that is inadequately modified may prevent stent expansion; excessive dilatation may damage the vessel wall. Calcium-modification devices require appropriate selection and technique because each has its own limitations and risks. Implantation quality is assessed not only by visual reduction of stenosis but also by expansion, apposition, edge integrity and flow through the affected branches.
Antithrombotic therapy is integral to procedural safety. Anticoagulation during the intervention limits thrombus formation on instruments and within the vessel; antiplatelet treatment protects the treated segment after implantation. Dosage, timing, kidney function, interactions and existing medications must be coordinated. Insufficient effect promotes thrombosis, whereas excessive effect increases bleeding. Unplanned discontinuation after discharge can contribute to events; therefore, device and strategy selection must take into account from the outset whether the prescribed treatment can realistically be followed.
The vessel wall may be injured in a way that separates its layers and creates a false lumen or intramural hematoma. Iatrogenic coronary dissection may remain localized or compress the true lumen, propagate and compromise important branches. Injury may result from the guiding catheter, guidewire passage or dilatation. Severity does not depend solely on angiographic appearance: location, extent, stability and consequences for flow determine how urgently it must be corrected.
When injury extends through the vessel wall, a coronary perforation occurs. Blood may collect in the pericardium and cause tamponade, but some perforations present less immediately or drain into other sites. Distal guidewire injuries may become apparent after an initially uneventful interval. The absence of hypotension at the first assessment therefore does not exclude later deterioration; anatomical location and persistent leakage guide containment and monitoring.
Coronary stent thrombosis results from interactions between the implanted surface, segment geometry, vascular response and the patient's thrombotic state. Underexpansion, edge defects, disturbed flow and inadequate antiplatelet protection may act together with later biological mechanisms. Occlusion may be abrupt and cause extensive infarction or cardiac arrest. The timing of the event helps formulate hypotheses but does not identify its cause on its own: defining the mechanism is essential to avoid repeating an implantation with the same defect.
Progressive narrowing of the lumen within the treated segment is instead termed in-stent restenosis. It may reflect neointimal proliferation, neoatherosclerosis and mechanical factors such as underexpansion or stent fracture. It is distinct from thrombosis, although it may contribute to acute presentations. Time since treatment, tissue type and the structural defect influence treatment choice; simply adding another metal layer may be ineffective if the underlying problem remains uncorrected.
Reopening the epicardial artery does not guarantee tissue perfusion. In the no-reflow phenomenon, distal embolization, ischemic and reperfusion injury, edema and vasomotor dysfunction impede microcirculatory flow. Before attributing reduced flow to this mechanism, correctable epicardial obstructions, such as dissection, residual thrombus, spasm or stent problems, must be excluded. This distinction changes treatment: a drug targeting the microcirculation will not resolve compression of the true lumen.
Other events include side-branch occlusion, spasm, embolization of material or air, and loss or entrapment of devices. Branch closure may be due to plaque shift, thrombosis or dissection and has different consequences depending on the territory supplied. Device-related incidents require assessment of position, embolization risk, ischemia and possibilities for percutaneous or surgical retrieval. These are heterogeneous situations in which repeated, unplanned attempts may worsen the initial injury; the strategy must maintain control of anatomy and perfusion.
A critical reduction in coronary flow restricts oxygen delivery and causes metabolic, electrical and contractile changes. The extent of injury depends on duration, territory, collateral circulation and the myocardial condition before the intervention. A brief occlusion may resolve without extensive necrosis; persistent impairment of a major vessel may cause ventricular dysfunction, pulmonary edema and shock. Ischemia and reperfusion may also promote ventricular arrhythmias or conduction disorders, which in turn worsen perfusion.
Cardiac tamponade impairs cardiac filling by increasing pericardial pressure. The speed of fluid accumulation may be more important than the absolute volume: rapid accumulation can cause collapse with relatively small amounts. Shock from extracardiac bleeding instead results from loss of circulating volume, whereas cardiogenic shock predominantly reflects pump failure. These mechanisms may coexist after complex PCI. Identifying the predominant contribution avoids inappropriate interventions, such as attributing all hypotension solely to ventricular dysfunction.
Acute kidney injury after the procedure may have several causes: hypoperfusion, congestion, embolization, medications, infection and a possible contribution from contrast medium. The term contrast-associated kidney injury describes a temporal association; attributing causality to contrast requires greater caution. A patient with kidney disease, hemodynamic instability or concurrent exposures has a different risk from a stable patient with preserved renal function. This distinction makes it possible to prevent modifiable factors without reducing every rise in creatinine to a single mechanism.
Arterial access may be complicated by hematoma, persistent bleeding, pseudoaneurysm, arteriovenous fistula, dissection, thrombosis or distal ischemia. After femoral access, retroperitoneal bleeding may cause hypotension, abdominal or lumbar pain and a fall in hemoglobin without an obvious groin hematoma. After radial access, occlusion may be asymptomatic because of collateral hand circulation, but remains relevant for future access; severe pain, sensory deficits or signs of ischemia require urgent assessment. Forearm bleeding with increasing tension may threaten the tissues even when the puncture site appears unremarkable.
Non-access-site bleeding may involve the gastrointestinal tract, urinary tract or other areas and reflect underlying disorders exacerbated by antithrombotic treatment. Severity is defined by site, blood loss, instability and need for transfusion or intervention, not merely by the presence of visible blood. Anemia may increase ischemia, and bleeding may prompt drug interruptions that expose the patient to thrombosis. The ARC-HBR consensus provides a framework for identifying high bleeding risk before PCI, but clinical decisions must also consider the postprocedural course.
Neurological events, including stroke, may result from embolization or altered perfusion and require a dedicated urgent care pathway. New focal deficits, aphasia or an unexplained change in consciousness must not automatically be attributed to sedation. Hypersensitivity reactions to contrast or other materials may cause cutaneous, respiratory or circulatory manifestations, to be distinguished from vagal responses and other causes of hypotension. Prolonged procedures also entail higher radiation doses, with possible delayed skin injury when exposure is high; documenting the dose and selective surveillance are part of management.
Persistent or recurrent chest pain after PCI requires assessment in relation to its intensity, duration, ECG findings and stability. It may reflect ischemia of the treated segment, branch occlusion, spasm, pericarditis or extracardiac causes; the sensation of pain alone cannot distinguish these conditions. Sudden recurrence after a symptom-free interval, particularly with sweating, dyspnea or electrical changes, increases suspicion of an ischemic complication. During the initial hours, a biomarker that has not yet risen does not exclude an ongoing event and must not delay urgent investigation.
Dyspnea may reflect ischemia, ventricular dysfunction, arrhythmia, anemia or a systemic complication. Syncope and hypotension require prompt investigation for arrhythmia, coronary occlusion, tamponade and hemorrhage. A more gradual decline in exercise capacity may instead suggest recurrent ischemia, heart failure or other illnesses. Later recurrence of angina does not itself establish restenosis: disease may progress elsewhere, and microvascular or vasomotor dysfunction may coexist.
The procedural history must establish the indication, treated vessel, devices used, any technical difficulties, final outcome and discharge recommendations. Vascular access, contrast volume, radiation exposure, baseline kidney function and initial blood values are relevant. Medication reconciliation establishes actual antiplatelet intake, vomiting, difficulties obtaining medicines, interruptions for procedures and concomitant anticoagulant use. The reasons for discontinuation must be understood without automatically treating it as the sole explanation for a thrombotic event, which may also have a mechanical component.
The physical examination includes peripheral perfusion, mental status, blood pressure, heart rate, oxygen saturation and signs of congestion. The access site, abdomen, back and affected limb are examined when bleeding or ischemia is suspected. Pulses, temperature, sensation and compartment tension may reveal vascular injury; limited bruising does not exclude deep bleeding. Cardiopulmonary assessment seeks new signs of dysfunction and guides echocardiography. In unstable presentations, these observations must proceed alongside treatment and activation of the catheterization laboratory or other required specialists.
Serial ECGs can identify new or dynamic abnormalities and compare them with those of the initial event. Monitoring detects arrhythmias and conduction disturbances; echocardiography assesses regional wall motion, global function, pericardial effusion and potential mechanical causes of deterioration. Complete blood count, creatinine, electrolytes and relevant anticoagulation tests complete the assessment as indicated. Troponin documents myocardial injury, but its concentration must be interpreted in relation to its time course, previous level and ischemic context. Not every postprocedural rise represents a new infarction.
The 2026 fifth universal definition distinguishes primary, secondary and procedure-related infarction, replacing the previous numerical classification. For procedure-related infarction, it considers a complication occurring within 30 days, with acute myocardial injury and ischemic manifestations. If the complication occurs during the intervention, or the intervention treats an acute infarction, both evidence of the coronary complication and a new regional wall-motion abnormality or loss of viable myocardium consistent with ischemia are required. Following an initially uncomplicated procedure, confirmation may come from either type of evidence in the relevant territory. A universal troponin threshold considered in isolation from the clinical context and imaging is insufficient. The older designations remain in historical studies and must be interpreted according to the definition used at that time.
Urgent coronary angiography is central when there is suspicion of acute occlusion, persistent ischemia, instability or threatening arrhythmias consistent with a coronary complication. It is inappropriate to await the full evolution of biomarkers before restoring compromised flow. The examination identifies the vessel, segment and branch status, often allowing diagnosis and treatment in the same session. Formal classification of the injury is completed using subsequent data and must not obstruct treatment of ongoing ischemia.
For a suspected access-site complication, duplex ultrasonography can characterize pseudoaneurysm, fistula, thrombosis and distal flow. CT is useful when deep or retroperitoneal bleeding must be clarified, provided the patient's condition permits diagnostic imaging. In unstable patients, source control and resuscitation take priority, and imaging must be selected without unnecessary delay. New renal dysfunction instead requires comparison with baseline, urine-output assessment and identification of hemodynamic or drug-related factors, avoiding automatic causal attribution.
Intracoronary imaging with intravascular ultrasound, IVUS, or optical coherence tomography, OCT, can reveal features that angiography alone does not define: stent expansion, apposition, edge dissections, calcium distribution and in-stent tissue characteristics. The two modalities have different strengths and limitations; selection depends on the required resolution, anatomy, hemodynamic conditions and contrast requirements. In thrombosis or restenosis, identifying the defect enables targeted correction and reduces the risk of adding devices without resolving the cause.
Measurements of coronary physiology may clarify the significance of residual stenoses or other lesions in stable patients and appropriate settings. They do not replace treatment of an obvious occlusion, and their interpretation may be altered by acute microcirculatory abnormalities. Noninvasive ischemia testing and functional imaging have a role in the deferred assessment of persistent or recurrent symptoms when immediate invasive examination is not required. The aim is to link symptoms, territory and mechanism, avoiding both automatic repeat PCI and underestimation of demonstrable ischemia.
Cardiac magnetic resonance imaging, when indicated and feasible, can establish injury distribution, viability and alternative diagnoses in cases not clarified by the initial evaluation. Assessment of ventricular function after the acute phase helps distinguish transient dysfunction from persistent damage and guides heart-failure treatment and arrhythmic risk stratification. Bleeding and renal risks must also be reassessed after an event: a complication changes the benefit–risk balance of later treatments and may require a different plan from the one drawn up before the intervention.
Initial management combines stabilization and control of the cause. Respiratory and circulatory support, treatment of arrhythmias and correction of metabolic disturbances accompany restoration of perfusion or hemostasis. Mechanical circulatory support may be considered in selected patients according to mechanism, severity and potential for recovery, without replacing correction of the responsible lesion. Communication among the interventional cardiologist, clinical cardiologist, anesthesiologist and, when necessary, cardiac or vascular surgeon is particularly important when ischemia, bleeding and shock coexist.
In epicardial flow compromise, intervention aims to restore a true lumen and adequate flow while preserving branches and territories. Acute thrombosis requires urgent treatment and reassessment of its mechanism and antithrombotic protection; dissection with ischemia may require a percutaneous or surgical solution depending on location and extent. No-reflow first requires exclusion of mechanical causes, followed by measures targeting the microcirculation and perfusion pressure. Intracoronary drugs are selected according to hemodynamics and contraindications; an angiographic response does not always guarantee complete tissue recovery.
With perforation, containment of leakage, assessment of anticoagulation and echocardiographic monitoring must proceed rapidly. Depending on location and vessel size, temporary balloon occlusion, a covered stent or distal embolization techniques may be used; tamponade may require pericardial drainage and sometimes surgery. The choice entails trade-offs between hemostasis and preservation of flow. Once angiographic control has been achieved, surveillance remains necessary because a pericardial collection may progress or become clinically apparent later.
Major bleeding requires identification and control of its source, hemodynamic support and consideration of reversing the antithrombotic effect. Drug interruption must be tailored to severity and recent stent placement: a small bruise and potentially fatal hemorrhage cannot be managed under one universal rule. Compression, endovascular treatment or surgery depend on the lesion; transfusion and other measures must be guided by the clinical context. Once hemostasis is secured, it is necessary to determine when and how to reinstate the required protection against ischemic events.
Restenosis and recurrent ischemia in stable conditions often allow planning based on anatomy, imaging and functional significance. The choice among percutaneous techniques, surgery and medical therapy depends on the mechanism, previous treatments and extent of coronary artery disease. Multiple stent layers, persistent calcification or diffuse disease make an overall strategy particularly important. Secondary prevention includes management of lipids and risk factors, smoking cessation, appropriate activity and rehabilitation, as well as treatment of diabetes, blood pressure and ventricular dysfunction.
Procedural prevention starts with an appropriate indication, risk assessment and access selection. The radial approach reduces many access-site bleeding complications in the studied settings, as documented by the MATRIX program, although it is not suitable for every technical situation. When femoral access is necessary, accurate puncture-site selection and hemostasis management remain crucial. Appropriate lesion preparation and implantation optimization reduce residual defects. In the RENOVATE-COMPLEX-PCI trial, intracoronary imaging guidance improved composite outcomes compared with angiography alone in the studied complex-PCI population; benefit depends on using the information to correct the result.
Renal protection includes baseline assessment, hemodynamic stability, reduction of unnecessary contrast and hydration when indicated, tailored to the risk of congestion. Avoiding preventable nephrotoxic exposures and planning follow-up tests in at-risk individuals is more useful than relying on a universal protective drug. PRESERVE found no benefit from bicarbonate compared with saline or from acetylcysteine compared with placebo for the evaluated renal and clinical outcomes in the patients studied. Kidney disease calls for a cautious strategy but should not delay urgent revascularization when the expected benefit is substantial.
Pharmacological prevention requires an explicit antiplatelet and anticoagulant plan, with duration and combinations tailored to the clinical syndrome, ischemic and bleeding risks and future procedures. Strategies following an acute coronary syndrome are not automatically the same as those after elective PCI. Any shortening, simplification or drug switch must be justified and coordinated; patients need to know whom to contact before independently stopping treatment. Gastrointestinal protection, adherence and access to medications can also influence long-term outcomes.
Prognosis depends on the injury sustained, how quickly it is recognized and whether the mechanism can be corrected. Limited injury identified and treated during the procedure may leave few consequences; prolonged occlusion, significant no-reflow, tamponade or major bleeding may substantially alter survival and recovery. Immediate technical success must therefore be distinguished from the overall clinical outcome, which includes ventricular function, renal function, bleeding, physical capacity and quality of life.
Follow-up assesses symptoms, adherence, adverse effects, blood pressure, lipids, kidney function and functional recovery according to individual risk. Routine follow-up coronary angiography is not required for every asymptomatic patient; investigations must address a clinical question or a specific procedure-related need. Patients who have experienced a complication require a plan that considers its mechanism: monitoring effusion after perforation, vascular assessment after access injury or renal reassessment after acute injury. Documentation of devices used and of the corrected problem facilitates future decisions.
Late consequences may include heart failure, reduced exercise capacity, arrhythmias, the need for further revascularization, deterioration of kidney function and limitations related to vascular or neurological injuries. Bleeding may influence antithrombotic choices for a long time; a complication experienced as sudden may undermine confidence in physical activity and treatment adherence. Rehabilitation and a clear explanation of the mechanism and residual risk help establish a sustainable course of care. Care does not end when the access site is closed or flow restored; it continues until residual function has been characterized and the most appropriate preventive strategy defined.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.